Latest Breaking News On - Lifesci advisors - Page 3 : comparemela.com

Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Natalie badilloCorey davisCrinetics pharmaceuticals incCompensation committee of crinetic board directorsCrinetics pharmaceuticalsHead of corporate communicationsLifesci advisorsCompensation committeeCrinetic boardInducement incentive award planNasdaq listing ruleNasdaq global select marketSci advisorsCorporate communications

Monthly information on share capital and company voting

(Article 223-16 of General Regulation of the French financial markets authority) PARIS, June 05, 2024 (GLOBE NEWSWIRE) Listing market: Euronext.

France generalPatricia sosa navarroArthur strilAshleyr robinsonPascalyne wilsonGeneral regulationSosa navarroInterim chief financial officerLifesci advisors

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesNorth carolinaNew yorkFrance generalAshleyr robinsonArthur strilMark frattiniPascalyne wilsonPatricia sosa navarroAmerican society of hematologyCellectis the company euronext growthEuropean medicines agencyEuropean unionSecurities exchange commissionCommittee for orphan medicinal productsEuropean commission

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell

United statesNorth carolinaFrance generalNew yorkPatricia sosa navarroPascalyne wilsonMark frattiniAshleyr robinsonArthur strilEuropean medicines agencyCellectis the company euronext growthAmerican society of hematologyEuropean commissionSecurities exchange commissionEuropean unionCommittee for orphan medicinal products

Cellectis S A : Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

PRESS RELEASE Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic.

France generalNorth carolinaUnited statesNew yorkPascalyne wilsonArthur strilSosa navarroSecurities exchange commissionAbout cellectisNasdaq global marketEuronext growthPrivate securities litigation reform actAnnual reportInterim chief financial officerLifesci advisors